Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE) Export

@article{citeulike:4275164, abstract = {AimsTo test whether angiotensin II receptor blockers (ARBs) therapy can reduce the incidence of cardiovascular events compared with non-ARB-based standard pharmacotherapy in coronary artery disease (CAD) patients with hypertension. Methods and resultsAngiographically documented CAD patients with hypertension were randomly assigned to receive either candesartan-based (n = 1024) or non-ARB-based pharmacotherapy including angiotensin-converting enzyme-inhibitors (n = 1025). The primary endpoint was the occurrence of a first major adverse cardiovascular event (MACE). There were 552 primary events during a median follow-up of 4.2 years: 264 (25.8\%) in the candesartan group and 288 (28.1\%) in the non-ARB group (hazard ratio, 0.89; 95\% confidence interval, 0.76-1.06). No significant differences existed between groups in terms of cardiovascular death (2.7 vs. 2.4\%, 1.14; 0.66-1.95), non-fatal myocardial infarction (2.8 vs. 2.5\%, 1.12; 0.66-1.88), or heart failure (3.9 vs. 4.3\%, 0.91; 0.59-1.40). New-onset diabetes was diagnosed significantly less frequently with candesartan than with non-ARBs (0.37; 0.16-0.89). Incidence of study drug discontinuation due to adverse events was lower with candesartan than with non-ARBs (5.7 vs. 12.2\%, P < 0.001). ConclusionAlthough candesartan showed no significant differences in MACE compared with the non-ARB treatment group, the drug significantly reduced the incidence of new-onset diabetes and was better tolerated. This study is registered as International Standard Randomised Controlled Trial No. UMIN000000790. 10.1093/eurheartj/ehp101}, author = {Kasanuki, Hiroshi and Hagiwara, Nobuhisa and Hosoda, Saichi and Sumiyoshi, Tetsuya and Honda, Takashi and Haze, Kazuo and Nagashima, Michitaka and Yamaguchi, Jun-Ichi and Origasa, Hideki and Urashima, Mitsuyoshi and Ogawa, Hiroshi and For}, citeulike-article-id = {4275164}, citeulike-linkout-0 = {http://dx.doi.org/10.1093/eurheartj/ehp101}, doi = {10.1093/eurheartj/ehp101}, journal = {Eur Heart J}, keywords = {acei, arb, cv, japan, rct}, month = {April}, pages = {ehp101+}, posted-at = {2009-04-05 03:38:58}, priority = {2}, title = {Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE)}, url = {http://dx.doi.org/10.1093/eurheartj/ehp101}, year = {2009} }

TY - JOUR ID - citeulike:4275164 L3 - citeulike-article-id:4275164 N2 - AimsTo test whether angiotensin II receptor blockers (ARBs) therapy can reduce the incidence of cardiovascular events compared with non-ARB-based standard pharmacotherapy in coronary artery disease (CAD) patients with hypertension. Methods and resultsAngiographically documented CAD patients with hypertension were randomly assigned to receive either candesartan-based (n = 1024) or non-ARB-based pharmacotherapy including angiotensin-converting enzyme-inhibitors (n = 1025). The primary endpoint was the occurrence of a first major adverse cardiovascular event (MACE). There were 552 primary events during a median follow-up of 4.2 years: 264 (25.8%) in the candesartan group and 288 (28.1%) in the non-ARB group (hazard ratio, 0.89; 95% confidence interval, 0.76-1.06). No significant differences existed between groups in terms of cardiovascular death (2.7 vs. 2.4%, 1.14; 0.66-1.95), non-fatal myocardial infarction (2.8 vs. 2.5%, 1.12; 0.66-1.88), or heart failure (3.9 vs. 4.3%, 0.91; 0.59-1.40). New-onset diabetes was diagnosed significantly less frequently with candesartan than with non-ARBs (0.37; 0.16-0.89). Incidence of study drug discontinuation due to adverse events was lower with candesartan than with non-ARBs (5.7 vs. 12.2%, P < 0.001). ConclusionAlthough candesartan showed no significant differences in MACE compared with the non-ARB treatment group, the drug significantly reduced the incidence of new-onset diabetes and was better tolerated. This study is registered as International Standard Randomised Controlled Trial No. UMIN000000790. 10.1093/eurheartj/ehp101 JF - Eur Heart J TI - Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE) SP - ehp101 KW - acei KW - arb KW - cv KW - japan KW - rct AU - Kasanuki, Hiroshi AU - Hagiwara, Nobuhisa AU - Hosoda, Saichi AU - Sumiyoshi, Tetsuya AU - Honda, Takashi AU - Haze, Kazuo AU - Nagashima, Michitaka AU - Yamaguchi, Jun-Ichi AU - Origasa, Hideki AU - Urashima, Mitsuyoshi AU - Ogawa, Hiroshi AU - For PY - 2009/04/04/ UR - http://dx.doi.org/10.1093/eurheartj/ehp101 ER -